Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
Antonio OmuroAlba A BrandesAntoine F CarpentierAhmed IdbaïhDavid A ReardonTimothy CloughesyAshley SumrallJoachim BaehringMartin J Van Den BentOliver BährGiuseppe LombardiPaul MulhollandGhazaleh TabatabaiUlrik LassenJuan Manuel SepulvedaMustafa KhasrawElodie VauleonYoshihiro MuragakiAnna Maria Di GiacomoNicholas ButowskiPatrick RothXiaozhong QianAlex Z FuYanfang LiuVon PotterAlexandros-Georgios ChalamandarisKay TatsuokaMichael LimMichael WellerPublished in: Neuro-oncology (2022)
The study did not meet the primary endpoint of improved OS; TMZ+RT demonstrated a longer median OS than NIVO+RT. No new safety signals were detected with NIVO in this study. The difference between the study treatment arms is consistent with the use of TMZ+RT as standard of care for glioblastoma.